Ocugen shares are trading lower. The company announced that the first patient has been dosed in its Phase 3 liMeliGhT clinical trial for OCU400—a modifier gene therapy product candidate being developed for retinitis pigmentosa.

6/20/24 11:25:40 AM ET

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

Get the next $OCGN alert in real time by email

Get the next $OCGN alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$OCGN

Date	Price Target	Rating	Analyst
10/15/2024	$4.00	Buy	Maxim Group
3/1/2023	$3.50	Neutral → Buy	Chardan Capital Markets
8/23/2022	$5.00	Buy	Mizuho
6/15/2022	$8.00	Buy	ROTH Capital
6/2/2022	$4.50	Overweight	Cantor Fitzgerald
2/28/2022	$10.00 → $8.00	Buy	HC Wainwright & Co.
7/26/2021		Outperform	Noble Capital Markets

More analyst ratings

$OCGN
Press Releases

Fastest customizable press release news feed in the world

Ocugen Provides Business Update with Fourth Quarter and Full Year 2024 Financial Results
Reached an alignment with FDA on Phase 2/3 pivotal confirmatory clinical trial for OCU410ST for Stargardt disease potentially expediting clinical development by two to three yearsCompleted dosing in OCU410 Phase 2 ArMaDa clinical trial (N=51) for geographic atrophy (GA). Data and Safety Monitoring Board (DSMB) recently reviewed interim safety data from Phase 2. All subjects from multiple dose levels in Phase 2 to date demonstrated a very favorable safety and tolerability profile.Positive 2-year long-term data across multiple mutations of retinitis pigmentosa (RP) from the Phase 1/2 clinical trial of OCU400 demonstrated a durable and statistically significant (p=0.005) improvement in visual f
3/5/25 7:02:00 AM ET
$OCGN
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Ocugen Announces Positive Opinion of EMA's Committee for Advanced Therapies for ATMP Classification for Novel Modifier Gene Therapy Candidate OCU410 for Geographic Atrophy and OCU410ST for Stargardt Disease
MALVERN, Pa., March 03, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ:OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that the European Commission has provided a positive opinion from the European Medicines Agency's (EMA) Committee for Advanced Therapies (CAT) for OCU410 and OCU410ST Advanced Therapy Medicinal Product (ATMP) classification. OCU410 is a novel, multifunctional modifier gene therapy candidate being developed for the treatment of patients with vision loss due to geographic atrophy (GA)—an advanced stage of dry age-related macular degeneration (dAMD)—and OCU410ST is being developed for Stargardt disease
3/3/25 9:00:00 AM ET
$OCGN
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Ocugen, Inc. Announces FDA Alignment on Phase 2/3 Pivotal Confirmatory Clinical Trial for Modifier Gene Therapy Candidate OCU410ST for Stargardt Disease
MALVERN, Pa., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ:OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that alignment has been reached with the U.S. Food and Drug Administration (FDA) to move forward with a Phase 2/3 pivotal confirmatory clinical trial for OCU410ST which, if positive, can be the basis of a biologics license application (BLA) submission. The GARDian trial for OCU410ST demonstrated: A favorable safety and tolerability profile with no serious adverse events related to OCU410ST, including no cases of ischemic optic neuropathy, vasculitis, intraocular inflammation, endophthalmitis or chor
2/27/25 8:46:50 AM ET
$OCGN
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care

$OCGN
Financials

Live finance-specific insights

Ocugen Provides Business Update with Fourth Quarter and Full Year 2024 Financial Results
Reached an alignment with FDA on Phase 2/3 pivotal confirmatory clinical trial for OCU410ST for Stargardt disease potentially expediting clinical development by two to three yearsCompleted dosing in OCU410 Phase 2 ArMaDa clinical trial (N=51) for geographic atrophy (GA). Data and Safety Monitoring Board (DSMB) recently reviewed interim safety data from Phase 2. All subjects from multiple dose levels in Phase 2 to date demonstrated a very favorable safety and tolerability profile.Positive 2-year long-term data across multiple mutations of retinitis pigmentosa (RP) from the Phase 1/2 clinical trial of OCU400 demonstrated a durable and statistically significant (p=0.005) improvement in visual f
3/5/25 7:02:00 AM ET
$OCGN
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Ocugen to Host Conference Call on Wednesday, March 5, 2025 at 8:30 A.M. ET to Discuss Business Updates and Fourth Quarter and Full Year 2024 Financial Results
MALVERN, Pa., Feb. 21, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ:OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines, today announced that it will host a conference call and live webcast to discuss the Company's fourth quarter and full year 2024 financial results and provide a business update at 8:30 a.m. ET on Wednesday, March 5, 2025. Ocugen will issue a pre-market earnings announcement on the same day. Attendees are invited to participate on the call using the following details: Dial-in Numbers: (800) 715-9871 for U.S. callers and (646) 307-1963 for international calle
2/21/25 8:00:45 AM ET
$OCGN
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Ocugen Provides Business Update with Third Quarter 2024 Financial Results
Subsequent to quarter-end, closed $30 million in debt financingOCU400 Phase 3 liMeliGhT clinical trial for retinitis pigmentosa (RP) on track to complete enrollment in 1H2025OCU410 is currently in Phase 2 of the Phase 1/2 ArMaDa clinical trial Data and Safety Monitoring Board (DSMB) for the OCU410ST GARDian clinical trial approved enrollment for the second phase of the Phase 1/2 clinical trialNew data on Phase 1/2 clinical trials for OCU410, OCU410ST and OCU400 to be presented at upcoming Clinical Showcase MALVERN, Pa., Nov. 08, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ:OCGN), a biotechnology company focused on discovering, developing, and commercializing novel
11/8/24 6:45:51 AM ET
$OCGN
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care

$OCGN
Leadership Updates

Live Leadership Updates

Ocugen Chairman, CEO & Co-founder, Dr. Shankar Musunuri, to Speak During U.S.-India Initiative on Critical and Emerging Technology Workshop
MALVERN, Pa., Sept. 09, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. ("Ocugen" or the "Company") (NASDAQ:OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, and vaccines, today announced that Dr. Shankar Musunuri, Chairman, Chief Executive Officer, and Co-founder of Ocugen, will speak during the workshop titled, "U.S.-India Biotechnology Cooperation: Realizing Benefits, Reducing Risks." This two-day event will take place from September 9-11, 2024 in New Delhi, India. "It is an honor to join the impressive group of thought leaders in this groundbreaking forum," said Dr. Musunuri. "There are endless opportunities to leverage the bes
9/9/24 6:30:12 AM ET
$OCGN
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Ocugen Set to Join Russell 3000® Index Effective June 28, 2024
MALVERN, Pa., May 28, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ:OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced its expected upcoming inclusion in the Russell 3000® Index, according to preliminary Russell reconstruction information posted on the FTSE Russell website. The newly reconstructed index will take effect after the market closes on June 28, 2024. "Inclusion of Ocugen to the Russell 3000® Index is our latest milestone, adding to what has already been a transformational year for the Company with three of our game-changing modifier gene therapies targeting
5/28/24 7:02:39 AM ET
$OCGN
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Ocugen, Inc. investors: Please contact the Portnoy Law Firm to recover your losses; June 10, 2024 deadline
Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, May 13, 2024 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Ocugen, Inc. ("Ocugen" or the "Company") (NASDAQ:OCGN) investors that a lawsuit was filed on behalf of investors that purchased Ocugen securities. Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 310-692-8883 or email: [email protected], to discuss their legal rights, or click here to join the case via www.portnoylaw.com. The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors' options for pursuing claims to recover their losses. On April 1, 2024, Ocugen filed a Cur
5/13/24 7:44:39 PM ET
$OCGN
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care

Ocugen shares are trading lower. The company announced that the first patient has been dosed in its Phase 3 liMeliGhT clinical trial for OCU400—a modifier gene therapy product candidate being developed for retinitis pigmentosa.

Chat with this insight

Recent Analyst Ratings for $OCGN

$OCGN Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Director Fernandes Prabhavathi bought $9,095 worth of shares (10,000 units at $0.91) (SEC Form 4)

Director Castillo Kirsten bought $22,848 worth of shares (25,000 units at $0.91), increasing direct ownership by 50% to 75,000 units (SEC Form 4)

$OCGN Press Releases

Fastest customizable press release news feed in the world

Ocugen Provides Business Update with Fourth Quarter and Full Year 2024 Financial Results

Ocugen Announces Positive Opinion of EMA's Committee for Advanced Therapies for ATMP Classification for Novel Modifier Gene Therapy Candidate OCU410 for Geographic Atrophy and OCU410ST for Stargardt Disease

Ocugen, Inc. Announces FDA Alignment on Phase 2/3 Pivotal Confirmatory Clinical Trial for Modifier Gene Therapy Candidate OCU410ST for Stargardt Disease

$OCGN Financials

Live finance-specific insights

Ocugen Provides Business Update with Fourth Quarter and Full Year 2024 Financial Results

Ocugen to Host Conference Call on Wednesday, March 5, 2025 at 8:30 A.M. ET to Discuss Business Updates and Fourth Quarter and Full Year 2024 Financial Results

Ocugen Provides Business Update with Third Quarter 2024 Financial Results

$OCGN SEC Filings

SEC Form S-8 filed by Ocugen Inc.

SEC Form 10-K filed by Ocugen Inc.

Ocugen Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

$OCGN Large Ownership Changes

This live feed shows all institutional transactions in real time.

Amendment: SEC Form SC 13G/A filed by Ocugen Inc.

Amendment: SEC Form SC 13G/A filed by Ocugen Inc.

SEC Form SC 13G filed by Ocugen Inc.

$OCGN Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

SEC Form 4 filed by Chief Accounting Officer Ramachandran Ramesh

Officer Upadhyay Arun covered exercise/tax liability with 41,633 shares, decreasing direct ownership by 12% to 306,197 units (SEC Form 4)

Chief Executive Officer Musunuri Shankar covered exercise/tax liability with 177,146 shares, decreasing direct ownership by 9% to 1,832,723 units (SEC Form 4)

$OCGN Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Maxim Group initiated coverage on Ocugen with a new price target

Ocugen upgraded by Chardan Capital Markets with a new price target

Mizuho initiated coverage on Ocugen with a new price target

$OCGN Leadership Updates

Live Leadership Updates

Ocugen Chairman, CEO & Co-founder, Dr. Shankar Musunuri, to Speak During U.S.-India Initiative on Critical and Emerging Technology Workshop

Ocugen Set to Join Russell 3000® Index Effective June 28, 2024

Ocugen, Inc. investors: Please contact the Portnoy Law Firm to recover your losses; June 10, 2024 deadline

Recent Analyst Ratings for
$OCGN

$OCGN
Insider Purchases

$OCGN
Press Releases

$OCGN
Financials

$OCGN
SEC Filings

$OCGN
Large Ownership Changes

$OCGN
Insider Trading

$OCGN
Analyst Ratings

$OCGN
Leadership Updates